ATE439592T1 - Proteingerüste für antikörper-nachahmer und andere bindende proteine - Google Patents

Proteingerüste für antikörper-nachahmer und andere bindende proteine

Info

Publication number
ATE439592T1
ATE439592T1 AT99967261T AT99967261T ATE439592T1 AT E439592 T1 ATE439592 T1 AT E439592T1 AT 99967261 T AT99967261 T AT 99967261T AT 99967261 T AT99967261 T AT 99967261T AT E439592 T1 ATE439592 T1 AT E439592T1
Authority
AT
Austria
Prior art keywords
binding proteins
protein scaffolds
antibody mimics
proteins
disclosed
Prior art date
Application number
AT99967261T
Other languages
English (en)
Inventor
Dasa Lipovsek
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22340181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE439592(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE439592T1 publication Critical patent/ATE439592T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99967261T 1998-12-10 1999-12-09 Proteingerüste für antikörper-nachahmer und andere bindende proteine ATE439592T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11173798P 1998-12-10 1998-12-10
PCT/US1999/029317 WO2000034784A1 (en) 1998-12-10 1999-12-09 Protein scaffolds for antibody mimics and other binding proteins

Publications (1)

Publication Number Publication Date
ATE439592T1 true ATE439592T1 (de) 2009-08-15

Family

ID=22340181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967261T ATE439592T1 (de) 1998-12-10 1999-12-09 Proteingerüste für antikörper-nachahmer und andere bindende proteine

Country Status (11)

Country Link
EP (2) EP1137941B2 (de)
JP (1) JP4562286B2 (de)
AT (1) ATE439592T1 (de)
AU (2) AU775076B2 (de)
CA (1) CA2351346C (de)
CY (1) CY1110549T1 (de)
DE (1) DE69941267D1 (de)
DK (1) DK1137941T4 (de)
ES (1) ES2329959T5 (de)
PT (1) PT1137941E (de)
WO (1) WO2000034784A1 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU783689B2 (en) 2000-01-24 2005-11-24 Adnexus Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
ES2564161T3 (es) * 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polipéptidos de anticuerpos artificiales
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
EP2141243A3 (de) * 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Proteingerüste für Antikörpermimetika und andere Bindungsproteine
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
AU2002307146B2 (en) * 2001-04-04 2007-02-01 University Of Rochester AlphaNuBeta3 integrin-binding polypeptide monobodies and their use
US20050214857A1 (en) * 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
DK2829283T3 (en) 2003-04-30 2017-09-18 Univ Zuerich METHOD OF TREATING CANCER USING IMMUNOTOXIN
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
ES2395839T3 (es) 2006-03-27 2013-02-15 Medimmune Limited Miembro de unión para el receptor GM-CSF
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
JP5638804B2 (ja) 2006-08-04 2014-12-10 アストラゼネカ アクチボラグ ＥｒｂＢ２に対する抗体
EP2068921B1 (de) 2006-10-19 2014-07-09 CSL Limited Hochaffine antikörper-antagonisten des interleukin-13-rezeptors alpha 1
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
JP5221641B2 (ja) 2007-04-02 2013-06-26 フィロゲン エスピーエー 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
EP2145021A2 (de) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarker und verfahren zur bestimmung der sensitivität gegenüber insulinwachstumsfaktor-1-rezeptormodulatoren
CN101754978B (zh) 2007-07-25 2013-06-05 菲洛根股份公司 一种与肺癌和淋巴瘤相关的抗原
SI2209805T1 (sl) 2007-10-30 2017-11-30 Philogen S.P.A. Antigen, povezan z revmatoidnim artritisom
RU2010121967A (ru) 2007-10-31 2011-12-10 Медиммун, Ллк (Us) Белковые каркасные структуры
DK2245064T3 (da) 2007-12-21 2014-10-27 Medimmune Ltd BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009083804A2 (en) * 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
JP2011517314A (ja) * 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Ｅｇｆｒに結合する操作されたタンパク質に基づく標的化された治療薬
US9296810B2 (en) * 2008-05-02 2016-03-29 Novartis Ag Fibronectin-based binding molecules and uses thereof
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
BRPI0919881B1 (pt) 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
EP2379116B1 (de) 2009-01-07 2015-08-26 Philogen S.p.A. Mit endometriose assoziierte antigene
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
EP2947096B1 (de) 2009-08-05 2018-11-28 Philogen S.p.A. Abzielung auf die neovaskulatur des knochenmarks
US20120270797A1 (en) * 2009-08-13 2012-10-25 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
ES2860453T3 (es) * 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
NO2504364T3 (de) 2009-11-24 2018-01-06
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
AU2011237365B2 (en) 2010-04-09 2015-01-29 Amgen Inc. BTNL9 proteins, nucleic acids, and antibodies and uses thereof
CA2796010C (en) 2010-04-13 2020-05-12 Medimmune, Llc Trail r2-specific multimeric scaffolds
JP5997134B2 (ja) 2010-04-30 2016-09-28 ヤンセン バイオテツク，インコーポレーテツド 安定したフィブロネクチンドメイン組成物、方法及び用途
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
MX354535B (es) 2010-09-01 2018-03-09 Genzyme Corp Star TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß.
CA2822515C (en) 2010-12-20 2023-04-25 Medimmune Limited Anti-il-18 antibodies and their uses
WO2012110824A1 (en) 2011-02-18 2012-08-23 Astrazeneca Ab Binding agents with specificity for a nucleic acid modification
ES2608835T3 (es) 2011-04-13 2017-04-17 Bristol-Myers Squibb Company Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
US9347058B2 (en) 2011-05-17 2016-05-24 Bristol-Myers Squibb Company Methods for the selection of binding proteins
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP2548891A1 (de) 2011-07-18 2013-01-23 Universiteit Maastricht Humaner monoklonaler Antikörper gegen die Gamma-Untereinheit des Acetylcholin-Rezeptors zur Verwendung bei der Behandlung von Rhabdomyosarkom
BR112014007469B1 (pt) 2011-09-27 2022-06-14 Janssen Biotech, Inc Método de fabricação de uma biblioteca de domínios de módulo de fibronectina tipo iii (fn3), biblioteca e método para obter um arcabouço de proteína
JP6239517B2 (ja) 2011-10-10 2017-11-29 メディミューン リミテッド 関節リウマチの治療法
KR20220116585A (ko) 2011-10-11 2022-08-23 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
WO2013056069A1 (en) 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
JP2015504038A (ja) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低減した免疫原性を有するフィブロネクチン結合ドメイン
PL2846836T3 (pl) 2012-05-07 2020-01-31 Allergan, Inc. Sposób leczenia amd u pacjentów opornych na terapię anty- vegf
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
HUE043482T2 (hu) 2012-09-13 2019-08-28 Bristol Myers Squibb Co Miosztatint megkötõ fibronektin alapú váz domén proteinek
US9695232B2 (en) 2012-10-03 2017-07-04 Philogen S.P.A. Anti-ED-A immunoconjugates for inflammatory bowel disease
EP2917238A1 (de) 2012-11-08 2015-09-16 Eleven Biotherapeutics, Inc. Il6-antagonisten und verwendungen davon
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP2953968B1 (de) 2013-02-06 2018-07-25 Bristol-Myers Squibb Company Fibronektin-typ-iii-domänenproteine mit erhöhter solubilität
ES2751735T3 (es) 2013-02-12 2020-04-01 Bristol Myers Squibb Co Métodos de replegado de proteínas a elevado pH
EP2968587A2 (de) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Serumalbumingebundene fibronectin-gerüstdomänen oder daran bindendes element
HK1218534A1 (zh) * 2013-03-14 2017-02-24 多伦多大学管理委员会 支架化肽文库以及其制备和筛选方法
GB201307501D0 (en) 2013-04-25 2013-06-12 Univ Aberdeen Anti-fungal antibody molecules and uses thereof
SG11201607818WA (en) 2014-03-20 2016-10-28 Bristol Myers Squibb Co Stabilized fibronectin based scaffold molecules
EP3129401B1 (de) 2014-03-20 2019-06-12 Bristol-Myers Squibb Company Serumalbuminbindende fibronectin-typ-iii-domänen
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
US11142571B2 (en) 2014-11-07 2021-10-12 Sesen Bio, Inc. IL-6 antibodies
EP3229909B1 (de) 2014-12-11 2020-10-14 Inbiomotion S.L. Bindeelemente für menschliches c-maf
CA2985816A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3353198B1 (de) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3-bindende fibronektin-basierte gerüstmoleküle
ES2781207T3 (es) 2015-09-23 2020-08-31 Bristol Myers Squibb Co Dominios de fibronectina de tipo iii de unión a seroalbúmina con velocidad de disociación rápida
EP3419599A4 (de) 2016-02-23 2019-09-11 Sesen Bio, Inc. Il-6-antagonistformulierungen und verwendung davon
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
SG11201808909WA (en) 2016-04-13 2018-11-29 Vivia Biotech Sl Ex vivo bite-activated t cells
CN109906232B (zh) 2016-09-23 2023-11-07 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
BR112019012154A2 (pt) 2016-12-14 2019-11-12 Janssen Biotech, Inc. domínios do tipo iii da fibronectina de ligação a cd8a
EP3554561B1 (de) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137-bindende fibronectin-typ-iii-domänen
EP3554535A4 (de) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Pd-l1-bindende fibronectin-typ iii-domänen
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
EP4328241A3 (de) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispezifische moleküle mit einer nichtimmunglobulin-heterodimerisierungsdomäne und verwendungen davon
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3720881A1 (de) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispezifische moleküle und verwendungen davon
EP3502139A1 (de) 2017-12-19 2019-06-26 Philogen S.p.A. Antikörper gegen tumorantigene
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3765516A2 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunktionale moleküle und verwendungen davon
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN113164777B (zh) 2018-09-27 2024-12-13 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7706373B2 (ja) 2019-02-21 2025-07-11 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
EP3927745A1 (de) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunktionsmoleküle, die an t-zellen binden, und deren verwendung zur behandlung von autoimmunerkrankungen
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
KR20230028242A (ko) 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
KR20230074144A (ko) 2020-08-26 2023-05-26 마렝고 테라퓨틱스, 인크. NKp30에 결합하는 항체 분자 및 이의 용도
JP2024515591A (ja) 2021-04-08 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｃｒに結合する多機能性分子およびその使用
US12239710B2 (en) 2021-04-14 2025-03-04 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
IL307582A (en) 2021-04-14 2023-12-01 Aro Biotherapeutics Company CD71-binding domains of the fibronectin type
CA3229003A1 (en) 2021-08-25 2023-03-02 Kothai Nachiar Devi PARTHIBAN Preparation of libraries of protein variants expressed in eukaryotic cells
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
EP4608861A1 (de) 2022-10-24 2025-09-03 F. Hoffmann-La Roche AG Vorhersage der reaktion auf il-6-antagonisten
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
CN121729490A (zh) 2023-06-06 2026-03-24 艾恩塔斯有限公司 真核细胞中表达的双特异性结合物文库的制备
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0971946T3 (da) * 1997-01-21 2006-10-30 Gen Hospital Corp Selektion af proteiner ved anvendelse af RNA-protein-fusioner
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US11054998B1 (en) 2019-12-12 2021-07-06 Facebook, Inc. High bandwidth memory system with distributed request broadcasting masters

Also Published As

Publication number Publication date
ES2329959T5 (es) 2013-12-18
AU2357200A (en) 2000-06-26
PT1137941E (pt) 2009-10-15
JP4562286B2 (ja) 2010-10-13
AU2004218675A1 (en) 2004-11-04
EP1137941A4 (de) 2002-04-17
DK1137941T3 (da) 2009-12-14
EP2154535A1 (de) 2010-02-17
AU775076B2 (en) 2004-07-15
EP1137941B2 (de) 2013-09-11
DK1137941T4 (da) 2014-01-06
CA2351346C (en) 2015-09-01
AU2004218675B2 (en) 2008-02-28
EP1137941B1 (de) 2009-08-12
WO2000034784A9 (en) 2000-11-16
CY1110549T1 (el) 2015-04-29
CA2351346A1 (en) 2000-06-15
ES2329959T3 (es) 2009-12-02
DE69941267D1 (de) 2009-09-24
JP2002532072A (ja) 2002-10-02
EP1137941A1 (de) 2001-10-04
WO2000034784A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
CY1110549T1 (el) Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης
AU4185001A (en) Protein scaffolds for antibody mimics and other binding proteins
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
DK2233498T3 (da) Kallikrein-inhiberende Kunitz-domæneproteiner og nukleinsyrer, der koder for disse
ATE328896T1 (de) Faktor viii vom schwein und hybriden
ATE529509T1 (de) Selektion von proteinen unter verwendung von rna- protein-fusionen
ATE333094T1 (de) Verfahren zur herstellung von protein-beladenen mikropartikeln
ATE353138T1 (de) Verfahren zur stabilisierung und messung von troponinkomplexen
ATE394484T1 (de) Smad 6 und dessen anwendungen
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
DE69828341D1 (de) Maschine zur Prüfung von Werkstoffen
DK0795605T3 (da) Denatureret lavdensitetslipoprotein-receptor
ATE220558T1 (de) Verbessertes verfahren zur stabilisierung von proteinen
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DE69902796D1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
DE69831229D1 (de) Schnelle bestimmung des verhältnisses von biologischen molekülen
DE68917273D1 (de) Testmethode und Gerät zur Bestimmung des gesamten Proteins.
DE59706714D1 (de) Verfahren zur kodierung von sendungen
DE69738323D1 (de) Verfahren zur verringerung der abbaubarkeit von futterprotein
DE69828551D1 (de) Maschine zur Prüfung von Werkstoffen
DE69618536D1 (de) Verfahren zur Inaktivierung von Viren in Proteinen
ATE147861T1 (de) Funktioneller test zur bestimmung der protein s- aktivität
DE59105196D1 (de) Verfahren zur prüfung von anordnungen.
ATE385573T1 (de) Verfahren zum identifizieren von liganden der rna-polymerase sigma 70 untereinheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1137941

Country of ref document: EP